MAM domain containing 2 is a potential breast cancer biomarker that exhibits tumour-suppressive activity

Cell Prolif. 2020 Sep;53(9):e12883. doi: 10.1111/cpr.12883. Epub 2020 Jul 24.

Abstract

Objectives: The aim of this study was to discover new potential biomarkers of breast cancer and investigate their cellular functions.

Materials and methods: We analysed the gene expression profiles of matched pairs of breast tumour and normal tissues from 24 breast cancer patients. Tetracycline-inducible MAMDC2 expression system was established and used to evaluate cell proliferation in vitro and in vivo. MAMDC2-mediated signalling was determined using immunoblot analysis.

Results: We identified MAMDC2 as a down-regulated gene showing significant prognostic capability. Overexpression of MAMDC2 or treatment with MAMDC2-containing culture medium significantly inhibited the cell proliferation of T-47D cells. Furthermore, MAMDC2 expression reduced in vivo growth of T-47D xenograft tumours. MAMDC2 may exert its growth-inhibitory functions by attenuating the MAPK signalling pathway.

Conclusion: We report that MAMDC2 has a tumour-suppressive role and, as a secretory protein, it might be useful as a biomarker for breast cancer treatment.

Keywords: biomarkers; breast cancer; cell proliferation; tumour suppressor.

MeSH terms

  • Animals
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Breast / pathology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Cell Proliferation
  • Down-Regulation*
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Genes, Tumor Suppressor
  • Glycosylation
  • Humans
  • Mice
  • Middle Aged

Substances

  • Biomarkers, Tumor